Positive data for guselkumab for psoriatic arthritis in two year long term trial

Findings from the long term Phase III DISCOVER-2a trial found 56% & 55% of patients who took guselkumab every four and every eight weeks respectively, experienced at least a ACR50 response at 100 weeks. Complete skin clearance was observed in 62% & 55% of patients respectively.

Source:

Biospace Inc.